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ABSTRACT 
 
Topic applications of Calendula officinalis L. lipophilic extracts are used in phytotherapy to 
relieve skin inflammatory conditions whereas infusions are used as a remedy for gastric 
complaints. Such a different usage might be explained by some cytotoxicity of lipophilic extracts 
at gastric level but little is known about this. Therefore, we screened the CH2Cl2 extract from the 
flowers of C. officinalis by MTT and LDH assays in human epithelial gastric cells AGS. This 
bioassay-oriented approach led to the isolation of several sesquiterpene glycosides which were 
structurally characterized by spectroscopic measurements, chemical reactions and MM 
calculations. The conformational preferences of viridiflorol fucoside were established and a 
previously assigned stereochemistry was revised. The compounds 1a, 2a and 3d showed 
comparably high cytotoxicity in the MTT assays, whereas the effect on LDH release was lower. 
Our study provides new insights on the composition of C. officinalis extracts of medium polarity 
and identifies the main compounds that could be responsible for cytotoxic effects at gastric level.  
 
 
Keywords : Calendula officinalis; Asteraceae; Marigold; sesquiterpene glycoside; viridiflorol; 
ledol; α-elemol; β-eudesmol. 
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1. Introduction 
Calendula officinalis L. is a plant widely cultivated for ornamental and medicinal purposes. C. 
officinalis is also being exploited as an industrial crop because of the high content of oil in its 
seeds (around 20%, of which about 60% is the unusual calendic acid) (Dulf et al., 2013). 
Several reviews covering a variety of biological activities of C. officinalis have been recently 
published (Singh et al., 2011) and a multitude of phytochemical constituents have been identified 
(Muley et al., 2009). Many classes of chemical compounds occur in C. officinalis extracts, 
including volatile oils (Kaškoniené et al., 2011), carotenoids (Kishimoto and Ohmiya, 2009), 
fatty acids, triterpenoids, flavonoids, saponins (Szakiel et al., 2005) and polysaccharides. 
Reviews published on this topic (Andersen et al., 2010; Muley et al., 2009), do not report the 
presence of sesquiterpene glycosides and the studies on them have been neglected in comparison 
to the main components occurring in C. officinalis. Nonetheless, these glycosides are present in 
relatively significant amount. Several articles, appearing during the years 1987-2001, described 
the isolation and the structural elucidation of 24 new compounds (De Tommasi et al., 1990; 
Jakupovic et al., 1988; Marukami et al., 2001; Pizza and De Tommasi, 1988).  
Clinical trials provide considerable evidence on the therapeutic effects of C. officinalis in the 
acceleration of wound healing and prevention of acute dermatitis (Cravotto et al., 2010). In fact, 
marigold apolar extracts are common ingredients of formulations for external use against local 
minor inflammations of the skin and mucosa (Campanini, 2003). The anti-inflammatory effect of 
these extracts is mainly due to the presence of fatty acid esters of pentacyclic triterpenols 
(Neukirch et al., 2004, 2005). Conversely, infusions from Marigold flowers have been 
traditionally consumed to relieve gastrointestinal inflammations including gastritis, ulcers and 
colitis (Campanini, 2003). The gastroprotective effect of these polar extracts might be due to the 
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presence of saponins (Yoshikawa et al., 2001). To sum up, apolar extracts are not recommended 
for ingestion whilst infusions do not contain the esterified triterpene alcohols.  
 
 
Fig. 1. Structural formulae of compounds 1, 2, 3 and their related ester moieties a-f. 
 
In order to gain further information on the composition and gastric toxicity of apolar 
compounds from C. officinalis, we carried out the purification and identification of secondary 
metabolites guided by their assays for cytotoxicity in human gastric epithelial cells (AGS). The 
CH2Cl2 extract of flowers was subjected to separation by flash chromatography (FC) on silica gel 
thus obtaining 16 fractions A-P (Supplementary Fig. S1). Cytotoxicity in human gastric AGS 
cells of all fractions A-P from the crude extract was tested by 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) and the fractions H and I were found to be toxic. This result 
was partially confirmed by the LDH assay (Supplementary Fig. S2). The pentacyclic triterpenoid 
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esters occurred in the fractions D-E at low polarity. Consequently, the components of the fraction 
H at medium polarity were separated by high pressure liquid chromatography (HPLC) on a 
reversed phase C18 (RP18) column, thus leading out to the elucidation of one new α-elemol 11-
O-β-D-(2'-acyl)-fucopyranoside, six (five of which are new) β-eudesmol 11-O-β-D-(2'-acyl)-
fucopyranosides and five (among them one is new) viridiflorol 10-O-β-D-(2'-acyl)-
fucopyranosides along with the two new α-elemol 11-O-β-D-fucopyranoside and β-eudesmol 11-
O-β-D-fucopyranoside (Fig. 1).  
 
2. Results and discussion 
2.1. Structural elucidation of compounds 1a and 1  
Compound 1a was isolated as white, amorphous powder; [α]25D –6.0 (c 0.17, CHCl3). The 
ESI-MS spectrum had a molecular ion peak [M-H]‾ at m/z 449 (Supplementary Fig. S60). The 
compound 1a was subjected to the reaction of acetylation (Subsection 4.6.1) and the diacetate 
product obtained was used for the HREIMS measurements. The molecular ion peak [M]+ was 
measured at m/z 534.3187 (calcd. for C30H46O8, 534.3192). Therefore the compound 1a had 
molecular formula of C26H42O6 , implying 6 unsaturations. The 1D- and 2D-NMR spectra of 
compound 1a (first RP18-HPLC peak) revealed the following substructural units: 1) an angelate 
group (Fig.1, substr. a) on the basis of 1H-1H couplings, the long-range correlation of the 3H-5" 
protons with the conjugated carboxyl C-1" and the NOESY maps of the olefinic H-3" with both 
the methyls 3H-4" and 3H-5", 2) a hexopyranose sugar (Fig.1, substr. 1) which corresponded to a 
β-fucose on the basis of its COSY maps and coupling constants, 3) a C15H26O tertiary alcohol 
(Fig.1, substr. 1) which requires two double bonds and one cycle. According to 1H-13C long-
range correlations (Table 2), the ring consisted of a cyclohexane that linked one methyl and a 
vinyl group at the quaternary carbon C-10, an isopropenyl group at the tertiary carbon C-5 and a 
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dimethyl carbinol at the tertiary carbon C-7. The relative configuration was established on the 
basis of the coupling constants of H-5 and H-7 and NOESY maps (Supplementary Fig. S58). 
Therefore, the structural formula of the sesquiterpene alcohol corresponds to α-elemol. Finally, 
the coupling constant of H-1' indicated the β-configuration of the glycosidic bond that occurred at 
C-11 as established by their 1H-13C long-range correlation. The chemical shift and the HMBC 
maps of H-2' indicated the position of the angelate ester (Supplementary Fig. S59).  
 
Table 1.  
1H NMR (400 MHz, CDCl3) spectroscopic data (δ in ppm, multiplicity, J in Hz) for compounds 1, 
1a, 2, 2a, 3 and 3fa  
No. 1 1ab 2 2ab 3 3fb 3fb,c 
1α 5.74, dd (17.2, 11.0) 5.78, dd 1.23, dd (13.0, 3.6) 1.18, dd ~1.92, m ~1.88, m 1.92, m 
1β   ~1.42, m /a ~1.44, m    
2α/a 4.83, m 4.87, m ~1.52, m ~1.58, m ~1.54, m ~1.60, m 1.62, m 
2β/b 4.82, m      "      "      "      "      " 1.54, m 
3α/a 4.74, m 4.78, m 1.91, br.q (11.0) 1.96, br.q 1.18, m  1.25, m  1.26, m 
3β/b 4.51, br.s 4.54, br.s 2.22, br.d (13.3) 2.27, br.d ~1.72, m ~1.79, m 1.80, m 
4     ~1.88, m ~1.91, m 1.90, m 
5 1.86, dd (12.2, 3.0) 1.88, dd 1.66, br.d (11.0) 1.69, br.d (12.2) 1.77, m (9.0, 4.6, 4.4) 1.67, m (9.0, 4.6, 4.4) 1.69, m 
6α ~1.62, m ~1.61, m 1.63, br.d 1.64, dq (12.8, 2.7) 0.03, t (9.5) 0.03, t (9.5) 0.08, t 
6β 1.35, q (12.0) ~1.35, q 1.06, q (12.7) 1.07, q (12.1)    
7 1.44, tt (12.0, 3.0) ~1.43, tt 1.44, tt 1.43, tt 0.52, td (9.5, 9.5, 7.6) 0.55, td (9.5, 9.5, 7.6) 0.58, ddd 
8α ~1.61, m ~1.58, m 1.58, br.d 1.53, m ~1.50, m ~1.50, m  1.45, m 
8β ~1.23, m ~1.18, m 1.21, dq (13.0, 3.3) 1.23, m      "      " 1.55, m 
9α ~1.38, m ~1.37, m ~1.18, m ~1.24, m ~1.56, m ~1.55, m  1.60, m 
9β      "      " 1.36, br.d (13.0) 1.40, br.d ~1.70, m ~1.74, m  1.73, m 
12 1.14, s 1.15, s 1.14, s 1.15, s 0.91, s 0.84, s 0.90, s 
13 1.17, s 1.22, s 1.15, s 1.21, s 0.94, s 0.96, s 0.98, s 
14 0.92, s 0.94, s 0.62, s 0.66, s 1.10, s 1.18, s 1.18, s 
15 1.63, br.s 1.67, br.s 4.62, br.s 4.66, br.s 0.84, d (6.7) 0.86, d (6.7) 0.88, d  
(15b)   4.35, br.s 4.39, br.s    
1′ 4.30, d (7.5) 4.60, d 4.30, d (7.5) 4.60, d 4.32, d (7.4) 4.61, d (7.9) 4.65, d 
2′ 3.38, dd (7.5, 9.6) 4.94, dd 3.37, dd (7.5, 9.6) 4.94, dd 3.37, dd (7.4, 9.5) 4.90, dd (7.9, 9.5)  5.00, dd 
3′ 3.46, dd (9.6, 3.4) 3.67, dd 3.44, dd (9.6, 3.4) 3.67, dd 3.43, dd (9.5, 3.4) 3.62, br.dd (9.5, 4.0) ~3.63, m 
4′ 3.58, dd (3.4, 1.1) 3.71, dd 3.56, dd (3.4, 0.7) 3.71, dd 3.55, dd (3.4, 0.5) 3.68, br.dd (4.0, 1.0) ~3.63, m 
5′ 3.52, qd (1.1, 6.5) 3.64, qd 3.50, qd (0.7, 6.6) 3.63, qd 3.48, qd (0.5, 6.5) 3.58, qd (1.0, 6.5)  ~3.63, m 
6′ 1.22, d (6.5) 1.33, d 1.19, d (6.6) 1.32, d 1.18, d (6.5) 1.31, d (6.5)  1.24, d 
aThe assignments were based on COSY, edited HSQC and HMBC experiments. bFor signals of ester chains see Table 3 or Experimental Section.  
cProton spectrum recorded in CD3OD. 
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Table 2.  
13C NMR (100 MHz, CDCl3) spectroscopic data (δ in ppm, multiplicity, HMBC maps) for 
compounds 1, 1a, 2, 2a, 3 and 3fa.  
No. 1 1ab 2 2ab 3 3fb 
1 150.2, 
d 
14 150.1, 
d 
2, 14 41.1, t 14 41.0, t 14 54.4, d  14 53.8, d 14 
2 109.6, t  109.6, t  23.37, t  23.4, t  25.5, t  25.5, t  
3 111.8, t  111.7, t  36.8 t 15 36.7, t 15 28.8, t 15 28.7, t 15 
4 147.9, s 15 147.5, s 15 151.1, s 3, 5, 15b  150.8, s 3, 5, 15b  38.1, d  15 38.1, d 15 
5 52.8, d 1, 3, 14, 15 52.6, d 3, 14, 15 49.9, d 6β, 14, 15 49.6, d 6β, 14, 15 39.6, d 15 39.4, d 15 
6 28.2, t  27.7, t  24.8, t  24.4, t  22.2, d 12, 13 22.0, d 12, 13 
7 48.1, d 12, 13  48.3, d 12, 13 48.2, d 12, 13 48.4, d 12, 13 28.5, d  28.8, d 12, 13 
8 22.5, t  22.2, t  22.2, t  22.0, t  18.6, t  18.0, t  
9 39.9, t  39.7, t  41.8, t  41.7, t  37.0, t 14 38.1, t 14 
10 39.6, s 1, 2, 14 39.6, s 1, 2, 14 35.8, s 14 35.8, s 14 82.1, s 14, 1' 81.5, s 14, 1' 
11 80.0, s 12, 13, 1' 79.6, s 12, 13, 1'  80.2, s 12, 13, 1' 79.7, s 12, 13, 1' 18.5, s 6, 12, 13 18.4, s 6, 12, 13 
12 23.2, q  22.5, q  23.42, 
q 
 22.7, q  15.8, q  16.0, q  
13 24.4, q  25.0, q  24.3, q  24.8, q  28.5, q  28.6, q  
14 16.5, q  16.5, q  16.2, q  16.2, q  26.9, q  26.6 q  
15 24.6, q  24.5, q  105.0, t  105.2, t  16.1, q  16.1 q  
1′ 97.0, d  95.0, d  97.0, d  94.8, d  96.5, d  94.4, d  
2′ 71.5,c d  73.2, d  71.6,c d  73.2, d  71.6,c d  72.4, d  
3′ 73.8, d  73.6, d  73.9, d  73.6, d  74.0, d  74.0, d  
4′ 71.6,c d  71.8, d  71.5,c d  71.8, d  71.5,c d  71.9, d  
5′ 70.2, d  69.8, d  70.1, d  69.8, d  70.1, d  69.6, d  
6′ 16.3, q  16.4 q  16.2, q  16.4 q  16.1, q  16.4, q  
aThe assignments were based on DEPT, edited HSQC and HMBC experiments. Long-range 1H–13C correlations are from the stated carbon to the indicated 
hydrogen(s). bFor signals of ester chains see Table 3 or Experimental Section. cAssignments in the same column may be interchangeable; 
 
The stereochemical elucidation of 1a was achieved by chemical transformations. We 
subjected the crude fraction H to the condition of saponification and the mixture of reaction 
products to chromatography thus obtaining the pure compounds 1, 2 and 3 (Subsection 4.4). The 
HRESI mass of compound 1 confirmed the structural formula (Supplementary Fig. S61). We 
tried to carry out the enzymatic hydrolysis of the saponificated compounds 1, 2 and 3 but several 
enzymes failed to give the desired products. This prevented us from establishing the absolute 
configuration of α-elemol. Eventually, we subjected the products from the saponification 
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reaction, to acidic hydrolysis using a microwave assisted (Xiping and Yangde, 2008) procedure: 
the pure sugar gave a positive optical rotation thus proving it to be the (+)-D-fucose enantiomer. 
This result is in agreement with the absolute configuration of fucose that has been previously 
established either by X-ray crystallography (Takaoka et al., 1986) and chemical methods 
(Marukami et al., 2001).  
 
Table 3.  
NMR spectroscopic data of ester chains for compounds 2a, 2b, 2c, 2d, 2e, and 2fa  
No. 2a 2b 2c 2d 2e 2f 
1′′ 167.7, s  168.1, s  166.9, s  167.3, s  177.5, s  177.4, s  
2′′ 127.0, s  128.0, s  115.3, d 5.68, m (1.3) 113.7, d 
5.67, m 
(1.3) 34.1, d 
2.58, m 
(7.0) 41.0, d 
2.40, tq 
(6.9) 
3′′ 139.1, d 
6.11, qq 
(7.3, 
1.4) 
138.3, d 
6.91, qq 
(7.1, 
1.4) 
158.6, s  164.0, s  18.8, q 1.18, d (7.0) 27.0, t 
~1.70, m 
~1.50, m 
4′′ 15.8, q 
2.00, dq 
(7.3, 
1.5) 
14.5, q 
1.80, dq 
(7.1, 
1.2) 
27.5, q 1.90, d (1.3) 33.9, t 
2.18, qd 
(7.4, 
1.2) 
19.2, q 1.19, d (7.0) 11.5, q 
0.94, t 
(7.4) 
5′′ 20.4, q 
1.90, m 
(1.5, 
1.4) 
12.1, q 
1.84, m 
(1.4, 
1.2) 
20.5, q 2.17, d (1.3) 12.1, q 
1.07, t 
(7.4)   16.3, q 
1.15, d 
(6.9) 
6′′       19.0, q 2.17, d (1.2)     
aAssignments were based on COSY, edited HSQC and HMBC experiments. 13C NMR (100 MHz, CDCl3) spectroscopic data (δ in ppm, multiplicity). 1H NMR (400 
MHz, CDCl3) spectroscopic data (δ in ppm, multiplicity, J in Hz).  
 
α-elemol is not very commonly isolated from natural sources, its 11-O-α-xylopyranoside was 
isolated as triacetate from Iphiona scabra D.C. (Abdel-Mogib et al., 1989) whereas its 11-O-α-
D-arabinopyranoside was identified by spectral analysis in a mixture separated from Lessingia 
glandulifera A.Gray (Jolad et al., 1988). The more polar fraction M was also subjected to HPLC 
separation and furnished the pure compounds 1, 2 and 3 (Subsection 4.3). This paper reports, for 
the first time, the characterization of the natural products α-elemol 11-O-β-D-fucopyranoside 1 
and its 2'-O-angelate ester 1a (Fig. 1). 
 
 10 
2.2. Structural elucidation of compounds 2a–2f and 2 
Compound 2a was isolated as white, amorphous powder; [α]25D –10.0 (c 0.4, CHCl3). The ESI-
MS spectrum had a molecular ion peak [M-H]‾ at m/z 449 (Supplementary Fig. S60). In the 
HREIMS measurements, the diacetate product of 2a showed its ion peak [M]+ at m/z 534.3184 
(calcd. for C30H46O8, 534.3192). Therefore, 2a (third RP18-HPLC peak) had molecular formula 
of C26H42O6 and was the most abundant compound. Its 1D- and 2D-NMR spectra showed again 
the presence of a fucopyranose sugar esterified at C-2' by angelic acid and linked, by means of a 
β-glycosidic bond, to a tertiary alcohol which possessed a different structural formula because it 
implies one double bond and two cycles. Diagnostic HMBC correlation maps (Table 2) were 
observed: 1) from the exomethylene proton Hb-15, the methylene protons 2H-3 and the methyne 
proton H-5 to the olefinic singlet C-4, 2) from the methyl protons 3H-14 to the triplet C-1, the 
singlet C-10 and the doublet C-5, 3) from both the methyl protons 3H-12 and 3H-13 to the 
deshielded singlet C-11 and the doublet C-7, 4) from the anomeric proton H-1' to the same 
deshielded singlet C-11. Such a correlation pattern suggested a eudesmane arrangement of the 
carbon skeleton and precisely the β-eudesmol (Fig.1, substr. 2). The relative configuration was 
determined by the 1H-1H coupling constant values of H-5 and Hβ-6 and was also supported by 
NOESY maps (Supplementary Fig. S58). The product of saponification 2 was also isolated from 
the fraction M thus revealing itself as a new natural product. (Subsections 4.4 and 4.3). The 
compound 2a has been previously reported from Calendula persica C.A. Mey. and our data were 
identical to the ones reported in the literature except for a few assignments of the 13C chemical 
shifts (Jakupovic et al., 1988). ). The authors did not measure the optical rotation of 2a and we 
did not succeed in carrying out the enzymatic hydrolysis of 2, so the absolute configuration 
remains undetermined. Nevertheless, practically all natural β-eudesmol is the (+)-(5S,7R,10R) 
enantiomer.  
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The second RP18-HPLC peak consisted of a mixture of β-eudesmol 11-O-β-D-
fucopyranosides acylated at O-2' by tiglic / senecioic / isobutyric acids in the ratio 10:7:6 that we 
depicted as compounds 2b, 2c and 2d respectively (Fig. 1). Two compounds from the fifth RP18-
HPLC peak (Supplementary Fig. S1) revealed to be β-eudesmol fucosides acylated at O-2' by 
acids 2-methylbutyric 2e and (E)-3-methyl-2-pentenoic 2f (Fig. 1) in the ratio 1:4. The structures 
of minor compounds were unambiguously determined by spectroscopic analyses; their diagnostic 
NMR data and HREIMS measurements are reported in the experimental part. This is the first 
report on the isolation and structural elucidation of the natural products 2, 2b, 2c, 2d, 2e and 2f.   
 
2.3. Structural elucidation of compounds 3a–3d, 3f and 3 
Compound 3f was isolated as white, amorphous powder; [α]25D –6.8 (c 0.15, CHCl3). The ESI-
MS spectrum had a molecular ion peak [M-H]‾ at m/z 463 (Supplementary Fig. S60) and 
suggested a molecular formula of C27H44O6. The HREIMS (Supplementary Fig. S60) of the 
esterified fucose cation observed from fragmentation of the diacetate derivative of 3f (Subsection 
4.6.3) as well as the HRESIMS (Supplementary Fig. S61) of the compound 3 (Subsection 4.4) 
fully supported the composition of 3f. The structural formula of the pure compound 3f (sixth 
RP18-HPLC peak) possesses the β-D-fucopyranose unit as indicated by its usual pattern of 
signals in the 1H-NMR spectrum. Moreover, the proton-proton couplings, the Nuclear 
Overhauser effects of H-2" and the HMBC maps between the H-2', the H-2" and a conjugated 
carboxyl (Supplementary Fig. S59) proved the presence of a (E)-3-methyl-2-pentenoate ester (Fig. 
1 substr. f) and its location on the sugar ring. Thus, the terpene moiety must be tricyclic and its 
proton spectrum showed three singlet methyls, one doublet methyl and two methyne protons 
resonating at a very high field (δ 0.03 and 0.55) which denoted a cyclopropane ring. The 1H-13C 
long-range correlations (Table 2) proved that two singlet methyls were geminal and linked to the 
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cyclopropane ring whereas one quaternary carbon joined the third singlet methyl and the 
anomeric oxygen of the fucose. All these spectroscopic data were reminiscent of an 
alloaromadendrol backbone as previously described in Calendula spp. extracts (Jakupovic et al., 
1988; Pizza and De Tommasi, 1988).  
The comparison of our proton chemical shifts with those from the literature revealed that they 
were identical (Jakupovic et al., 1988; Pizza and De Tommasi, 1988). However, one author 
(Jakupovic et al., 1988) proposed the (10S) configuration (i.e. viridiflorol) whereas the other 
author (Pizza and De Tommasi, 1988) assigned the epimeric (10R) (i.e. ledol). Careful scrutiny of 
the literature, revealed that the differentiation of epimeric C-10 alloaromadendrols cannot be 
definitely established by NOE results because the 3H-14 shows a strong enhancement of H-1 but 
none of the cyclopropyl protons in either case (Hirota et al., 1996). In addition, not only is the 
value of the specific optical rotation of ledol low, closely resembling that of viridiflorol, but its 
sign is dependent of the solvent (Thamapipol and Kündig, 2011). Ledol and viridiflorol can be 
differentiated by their characteristic melting points or, more easily, by the chemical shifts of the 
cyclopropyl protons (Kaplan et al., 2000). On the basis of known 1H-NMR data (Fletcher et al., 
2000; Jakupovic et al., 1988; Pizza and De Tommasi, 1988) and ours, this latter criterion seems 
to be also applicable to viridiflorol glycosides; thus, all the Calendula species biosynthesize 
(10S)-viridiflorol (Fig. 1). Finally, the structure of officinoside D was elucidated as the 
diglycoside derivative of 13-hydroxyledol (Marukami et al., 2001). The authors subjected it to 
enzymatic hydrolysis and stated that the spectroscopic data of the reaction product matched those 
for flourensadiol (Kingston et al., 1975). But flourensadiol was proven to consist of 12-
hydroxyviridiflorol by X-ray crystallography (Pettersen et al., 1975). Therefore, the structure of 
officinoside D might need to be revised.  
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The (10S)-viridiflorol has also been identified as its 10-O-β-D-quinovopyranoside (Jakupovic 
et al., 1988) and 10-O-α-rhamnopyranoside (Fletcher et al., 2000). The fraction collected at 
tR=28.0 min (forth RP18-HPLC peak) contained two minor compounds which were identified as 
the new viridiflorol 10-O-β-D-(2'-tigloyl)-fucopyranoside 3b and the known viridiflorol 10-O-β-
D-(2'-senecioyl)-fucopyranoside 3c (Jakupovic et al., 1988) in the ratio of 4:5 (Supplementary 
Fig. S1). Two additional compounds from the fifth RP18-HPLC peak (Supplementary Fig. S1) 
were characterized as the known viridiflorol 10-O-β-D-(2'-isobutyryl)-fucopyranoside 3d and 
viridiflorol 10-O-β-D-(2'-angeloyl)-fucopyranoside 3a (De Tommasi et al., 1990). Only 
diagnostic NMR data of minor compounds are reported in the experimental part. The compound 
3, obtained by saponification of 3a and by separation of fraction M (Subsections 4.4 and 4.3) was 
previously reported as a natural product. The composition of the fraction I was similar to that of 
fraction H.  
 
2.4. MM calculation of compound 3f 
The most stable conformation of (10R)-ledol was calculated by a molecular mechanic (MM) 
software thus establishing that the cycloheptane ring adopts a boat like conformation (Freeman et 
al., 2008) with the 3H-14 in an equatorial orientation (Kaplan et al., 2000). Similarly, we 
undertook the MM calculation of the lowest energy conformer of (10S)-viridiflorol. The outcome 
of MM calculations for (10S)-viridiflorol proved that the 3H-14 still occupies an equatorial 
position but the cycloheptane ring has a chair like conformation (Freeman et al., 2008). This is 
consistent with the lack of NOE interactions between 3H-14 and the cyclopropyl protons. Since it 
was unequivocally established that the fucose moiety possessed the (+)-D stereochemistry, we 
further extended the MM calculations to compounds 3 and 3f. Assuming that we had the (10S)-
viridiflorol enantiomer in hand and by the sequential application of the dihedral driver routine to 
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the bonds C10-O10, O10-C1', C2'-O2', and C1"-C2", we obtained the lowest energy conformer 
which is shown in the Figure 2.  
    
Fig. 2. Molecular mechanics calculated lowest-energy conformer of compound 3f. 
 
This preferred conformation prompts the following comments: 1) the pyranose ring turns its 
α-side toward the cyclopentane ring and the H-1' stays between H-1 and 3H-14, 2) the 3H-6' is 
directed outwards and the ester chain reaches out over the cyclopropane. Such an arrangement is 
supported by the intense NOEs of H-1' with both H-1 and 3H-14 as well as by the weak though 
noticeable NOEs of H-2" with both H-5 and 3H-12 (Supplementary Fig. S59). The presence of a 
carboxylic acid bound to the C-2' hydroxyl in 3, causes shifts of the NMR resonances for H-5, H-
6, H-7, 3H-12, 3H-13 and 3H-15 which with the unsaturated ester chains are mostly located up-
field while with the saturated ones are found down-field (Pizza and De Tommasi, 1988). This 
effect may be attributed to the anisotropic shielding cone of the conjugated C=C double bond. 
 15 
The difference between the resonances Δ(δsat─δunsat), calculated from our NMR data acquired 
in CDCl3, clearly show that the highest shielding effect applies to 3H-12.  
We also drew the compounds 3 and 3f with the (10R)-viridiflorol enantiomer and calculated 
the lowest energy conformer. In this minimized structure, the ester chain again reached out over 
the cyclopropane but the H-1' stayed between 3H-14 and Ha-9. This arrangement is inconsistent 
with the experimental NMR data thus pointing out that 3 is constituted by the (10S) enantiomer 
of viridiflorol. In conclusion, MM calculations agree with NMR data and the most stable 
conformation shown in Figure 2 matches the perspective drawing previously obtained by X-ray 
crystallography (Takaoka et al., 1986).   
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Fig. 3. Cytotoxicity of pure compounds 1a, 2a and 3f from fraction H by MTT test (panel A, 5-
20 µM) and by LDH assay (panel B, 5-20 µM). Triton-X100 1% was used as positive control, 
showing about 100% and 90% inhibition of cell viability for MTT and LDH assays, respectively.  
 
2.5. Cytotoxicity of 1a, 2a and 3f by MTT and LDH assays 
In order to identify the constituents responsible for the cytotoxic effect seen with fraction H, 
the pure compounds 1a, 2a and 3f were also assayed by MTT test. Individual compounds 1a, 2a, 
and 3f already showed high cytotoxicity at 10 µM (83%, 92% and 99%, respectively), thus 
suggesting these compounds are the most responsible for the cytotoxicity of the fraction H. The 
IC50 were as follows: 1a = 6.46 ± 0.011 µM; 2a = 5.42 ± 0.022 µM; 3f = 5.78 ± 0.96 µM (mean 
± S.D.). The three individual compounds possessed lower cytotoxicity in the LDH assay (24%, 
21% and 65% at 20 µM, respectively), thus mirroring the effect previously shown by H and I 
fractions. IC50 value of the most toxic compound 3f was 15.4 ± 0.05 µM (mean ± S.D.). 
Specifically, the extracts and pure compounds showed higher toxicity in the MTT than in the 
LDH assay. Indeed, it has been previously revealed that MTT assay gives greater sensitivity than 
the LDH assay; this could be due to the generation, by toxic compounds, of reactive oxygen 
species within the mitochondria leading to damage of mitochondrial components and giving signs 
of toxicity earlier than LDH release (Fotakis and Timbrell, 2006).  
In order to gain further information about the stability of these compounds in the stomach, the 
CH2Cl2 extract was subjected to in vitro gastric digestion, thus mimicking the gastric 
environment. The reactivity of the components was assessed by HPLC and most of the 
sesquiterpenes glycosides could still be detected after the treatment. Such a result indicated that 
these molecules are present in an unaltered form in the stomach. However, the metabolic fate and 
bioavailability of these compounds after passage through the stomach is still unknown.  
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3. Concluding Remarks  
Herbal medicines represent a promising source of lead compounds for drug development and 
also benefit from easy accessibility and low-cost availability. However, the past and future major 
challenge of herbal medicines is to demonstrate evidence-based therapeutic use. Our paper 
provides new insights on the components of medium polarity of C. officinalis extracts and 
identifies the main compounds that could be responsible for cytotoxic effects at gastric level, if 
highly concentrated. Therefore, varieties of C. officinalis with low content of sesquiterpene 
glycosides should be selected for cultivation for medicinal purposes. 
 
4. Experimental  
4.1. General experimental procedure  
Optical rotations were measured on a Bellingham+Stanley ADP 440 polarimeter. 1D and 2D 
NMR spectra were recorded on a Bruker Avance 400 spectrometer at 400 MHz (1H) and 100 
MHz (13C) in 5 mm BBI probe. Chemical shifts are reported in ppm (δ), using the residual 
solvents signals as internal reference (CDCl3 = 77.0, CHCl3 = 7.26 and CD2HOD = 3.31). 
Coupling constants (J) are in Hz. 1H and 13C NMR assignments were supported by 1H,1H COSY, 
1JCH (HSQC), nJCH (HMBC) and NOESY experiments. Selected HMBC (blue arrow, H → C) and 
key NOESY (red line) correlations of compounds 1, 2 and 3 are shown in the Supplementary data 
(Fig. S58); full HMBC and NOESY correlations for all compounds are given in the 
Supplementary data (Fig. S59). Electrospray ionization mass spectra (ESIMS) were recorded on a 
Bruker Esquire_LC multiple ion trap; capillary voltage 4000 V, nebulizing pressure 30.0 psi, 
drying gas flow 7 mL/min, temperature 300 °C. The HRESIMS detection was performed using a 
LTQ-Orbitrap hybrid mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) fitted 
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with an electrospray source (ESI) operating in positive ionization mode (Supplementary Fig. 
S61). Electron impact mass spectra (EIMS, HREIMS) were recorded on a Kratos MS80 
spectrometer with home-built data system; electron ionization at 70 eV, m/z (rel. %). For flash 
chromatography commercial silica gel Merck Kieselgel 60 (70-230 mesh) and Merck RP 18 
LiChroprep (40-65 µm) was used. Precoated silica gel plates Merck Kieselgel 60 PF254 were 
used for analytical TLC. HPLC separations were performed on a Merck Hitachi system equipped 
with an L7100 pump, an L7400 UV detector, a D7500 integrator and a manual Rheodyne injector. 
The following HPLC columns and methods were used: i) RP18 Synergi Hydro column (150×10 
mm, 4 µm particle size, 80 Å pore size; Phenomenex, Torrance, CA, USA), 5.0 mL/min, λ=254 
nm; for the fraction H the eluents were CH3CN (A) and CH3CN−H2O (50:50) (B) and the 
gradient was changed linearly from 0% to 85% A in 45 min; for the fraction M the eluents were 
CH3CN (A) and CH3CN−H2O (40:60) (B) and A was applied in the gradient of 0% at t=0, 0% at 
t=10, 37% at t=30, 85% at t=31, 85% at t=45, 100% at t=46 min; for the saponificated mixture 
the eluents were MeOH−H2O (75:25). ii) Allure Biphenyl column (150×4.6 mm, 5 µm particle 
size, 60 Å pore size; Restek, Bellefonte, PA, USA), 1.0 mL/min, λ=254 nm; the eluents were 
CH3CN (A) and CH3CN−H2O (50:50) (B) and A was applied in the gradient of 0% at t=0, 23% at 
t=30, 85% at t=35 min; iii) Luna CN column (150×4.6 mm, 3 µm particle size, 100 Å pore size; 
Phenomenex, Torrance, CA, USA), 0.8 mL/min, λ= 210, 254, 290 nm; the eluents were n-hexane 
(A) and i-PrOH (B) and B was applied in the gradient of 1% at t=0, 1% at t=5, 10% at t=35, 10% 
at t=50 min. The microwave-assisted hydrolysis experiments were performed with a Discover SP 
system (CEM, USA). Molecular mechanics (MM) calculations were carried out with the 
PCModel v9.100 computer program. Lactate dehydrogenase (LDH) Cytotoxicity Detection Kit 
was provided by Takara Bio Inc. (Otsu, Shiga, Japan). 3-(4,5-dimethylthiazol-2-yl)-2,5-
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diphenyltetrazolium bromide dye (MTT) and reagents for gastric digestion were provided by 
Sigma-Aldrich (Milan, Italy). 
 
4.2. Plant material  
Dry flowers of C. officinalis (variety Calypso Orange Florensis) were obtained and extracted 
as previously described (Neukirch et al., 2004). A voucher specimen (N. 20040929) is deposited 
at the Laboratory of Bioorganic Chemistry.  
 
4.3. Extraction and isolation  
A portion of the extract was subjected to FC on silica gel (Ø7 cm × 10 cm), gradually 
increasing the eluent polarity from n-hexane−EtOAc (95:5) to absolute ethyl acetate (300 mL 
fraction volume) and then washing with acetone (Supplementary Fig. S1). This procedure 
afforded 16 fractions. The fraction H (0.78 g) was collected with n-hexane−EtOAc 3:7; a portion 
(~100 mg) was submitted to HPLC on the RP18 column to yield six fractions that contained the 
following compounds: 1a (tR=24.0 min, mg 5.8); 2b+2c+2e (tR=25.1 min, mg 3.6), 2a (tR=26.9 
min, mg 22.6), 2a+3b+3c (tR=28.0 min, mg 2.3), 3e+3a+2d+2f (tR=29.2 min, mg 14.0), 3d 
(tR=31.7 min, mg 9.8). The peaks at tR=28.0 and 29.2 min were further separated by HPLC on the 
biphenyl column to yield respectively: two fractions containing 3b+3c (tR = 21.9 min, mg 1.0), 
2a (tR=23.5 min, mg 0.6) and three fractions containing 3e (tR=25.5 min, mg 0.8), 3a (tR=27.8 
min, mg 3.1), 2d+2f (tR=29.4 min, mg 4.4). Fraction M (0.10 g) was collected with acetone; a 
portion (~50 mg) was submitted to HPLC on RP 18 column with a gradient of CH3CN in H2O to 
yield several fractions. The fractions that interested us, contained the following compounds: 1 
(tR=16.5 min, mg 3.3), 2 (tR=18.1 min, mg 5.7), 3 (tR=21.8 min, mg 10.9).  
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4.3.1. Compound (1) 
White, amorphous powder; [α]25D +3.5 (c 0.28, isopropanol); 1H NMR (CDCl3, 400 MHz) see 
Table 1; 13C NMR (CDCl3, 100 MHz) see Table 2. HR-ESI-MS (positive mode): m/z 391.2459 
[M+Na]+; (calcd. for C21H36O5Na, 391.2455).  
 
4.3.2. Compound (1a):  
White, amorphous powder; [α]25D –6.0 (c 0.17, CHCl3); 1H NMR (CDCl3, 400 MHz) see 
Table 1 and δ 6.10 (1H, qq, J = 7.3, 1.4 Hz, H-3"), 2.00 (3H, dq, J = 7.3, 1.5 Hz, H-4"), 1.89 (3H, 
m, H-5"); 13C NMR (CDCl3, 100 MHz) see Table 2 and δ 169.5 (C, C-1"), 126.7 (C, C-2"), 139.0 
(CH, C-3"), 15.8 (CH3, C-4"), 20.3 (CH3, C-5"); ESI-MS (positive mode): m/z 473 [M+Na]+; 
MS2 of  [M+Na]+: m/z 269 [M+Na-C15H24]+; MS3 of [M+Na]+ → [M+Na-C15H24]+: m/z 251 
[M+Na-C15H24-H2O]+. ESI-MS (negative mode): m/z 449 [M-H]‾; MS2 of  [M-H]‾: m/z 367 [M-
H-C5H6O]‾; MS3 of [M-H]‾ → [M-H-C5H6O]‾: m/z 145 [M-H-C5H6O-C15H26O]‾.  
 
4.3.3. Compound (2) 
White, amorphous powder; [α]25D +33.3 (c 0.72, isopropanol); 1H NMR (CDCl3, 400 MHz) 
see Table 1; 13C NMR (CDCl3, 100 MHz) see Table 2. HR-ESI-MS (positive mode): m/z 
391.2458 [M+Na]+; (calcd. for C21H36O5Na, 391.2455).  
 
4.3.4. Compound (2a) 
White, amorphous powder; [α]25D +10.0 (c 0.4, CHCl3); 1H NMR (CDCl3, 400 MHz) see 
Tables 1 and 3; 13C NMR (CDCl3, 100 MHz) see Tables 2 and 3; ESI-MS (positive mode): m/z 
473 [M+Na]+; MS2 of  [M+Na]+: m/z 269 [M+Na-C15H24]+; MS3 of [M+Na]+ → [M+Na-
C15H24]+: m/z 251 [M+Na-C15H24-H2O]+. ESI-MS (negative mode): m/z 449 [M-H]‾; MS2 of  [M-
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H]‾: m/z 367 [M-H-C5H6O]‾; MS3 of [M-H]‾ → [M-H-C5H6O]‾: m/z 145 [M-H-C5H6O-
C15H26O]‾.  
 
4.3.5. Compound (2b) 
Solid mixture; 1H NMR (CDCl3, 400 MHz) see Table 3 and δ ~1.43 (1H, m, H-1β), 1.18 (1H, 
dd, H-1α), ~1.58 (2H, m, H-2), 2.28 (1H, brd, H-3β), 1.96 (1H, brq, H-3α), 1.68 (1H, brd, H-5), 
1.66 (1H, dq, H-6α), 1.05 (1H, q, H-6β), ~1.42 (1H, tt, H-7), ~1.53 (1H, m, H-8α), ~1.23 (1H, m, 
H-8β), 1.40 (1H, brd, H-9β), ~1.22 (1H, m, H-9α), 1.15 (3H, s, H-12), 1.21 (3H, s, H-13), 0.65 
(3H, s, H-14), 4.67 (1H, brs, H-15a), 4.36 (1H, brs, H-15b), 4.61 (1H, d, H-1'), 4.90 (1H, dd, H-
2'), 3.67 (1H, dd, H-3'), 3.71 (1H, dd, H-4'), 3.63 (1H, qd, H-5'), 1.33 (3H, d, H-6'); 13C NMR 
(CDCl3, 100 MHz) see Table 3. ESI-MS (positive mode): m/z 473 [M+Na]+; MS2 of  [M+Na]+: 
m/z 269 [M+Na-C15H24]+. EIMS of the diacetate: m/z 534 [M]+• (0.3), 313 [M-C15H25O]+ (16), 
204 [M-C15H22O8] +• (24), 83 (100). HREIMS: m/z 534.3189 (calcd for C30H46O8, 534.3193), 
313.1290 (calcd for C15H21O7, 313.1287).  
 
4.3.6. Compound (2c) 
Solid mixture; 1H NMR (CDCl3, 400 MHz) see Table 3 and δ 1.15 (3H, s, H-12), 1.21 (3H, s, 
H-13), 0.66 (3H, s, H-14), 4.67 (1H, brs, H-15a), 4.40 (1H, brs, H-15b), 4.56 (1H, d, H-1'), 4.81 
(1H, dd, H-2'), 1.33 (3H, d, H-6'); 13C NMR (CDCl3, 100 MHz) see Table 3. ESI-MS (positive 
mode): m/z 473 [M+Na]+; MS2 of [M+Na]+: m/z 269 [M+Na-C15H24]+. EIMS and HREIMS of 
the diacetate are identical to those for compound 2b.  
 
4.3.7. Compound (2d) 
 22 
Solid mixture; 1H NMR (CDCl3, 400 MHz) see Table 3 and δ ~1.45 (1H, m, H-1β), 1.17 (1H, 
dd, H-1α), ~1.58 (2H, m, H-2), 2.28 (1H, brd, H-3β), 1.96 (1H, brq, H-3α), 1.70 (1H, brd, H-5), 
1.65 (1H, dq, H-6α), 1.07 (1H, q, H-6β), ~1.43 (1H, tt, H-7), ~1.56 (1H, m, H-8α), ~1.23 (1H, m, 
H-8β), 1.40 (1H, brd, H-9β), ~1.25 (1H, m, H-9α), 1.17 (3H, s, H-12), 1.21 (3H, s, H-13), 0.66 
(3H, s, H-14), 4.67 (1H, brs, H-15a), 4.39 (1H, brs, H-15b), 4.57 (1H, d, H-1'), 4.84 (1H, dd, H-
2'), 3.64 (1H, dd, H-3'), 3.70 (1H, dd, H-4'), 3.62 (1H, qd, H-5'), 1.33 (3H, d, H-6'); 13C NMR 
(CDCl3, 100 MHz) see Table 3. ESI-MS (positive mode): m/z 487 [M+Na]+; MS2 of  [M+Na]+: 
m/z 283 [M+Na-C15H24]+. EIMS of the diacetate: m/z 548 [M]+• (0.1), 327 [M-C15H25O]+ (14), 
204 [M-C15H22O8] +• (19), 97 (100). HREIMS: m/z 548.3339 (calcd for C31H48O8, 548.3349), 
327.1445 (calcd for C16H23O7, 327.1444).  
 
4.3.8. Compound (2e) 
Solid mixture; 1H NMR (CDCl3, 400 MHz) see Table 3 and δ 1.17 (3H, s, H-12), 1.21 (3H, s, 
H-13), 0.68 (3H, s, H-14), 4.69 (1H, brs, H-15a), 4.42 (1H, brs, H-15b), 4.57 (1H, d, H-1'), 4.81 
(1H, dd, H-2'), 1.33 (3H, d, H-6'); 13C NMR (CDCl3, 100 MHz) see Table 3. ESI-MS (positive 
mode): m/z 461 [M+Na]+; MS2 of  [M+Na]+: m/z 257 [M+Na-C15H24]+. EIMS of the diacetate: 
m/z 301 [M-C15H25O]+ (15), 204 [M-C15H22O8] +• (24), 83 (100). HREIMS: m/z 301.1293 (calcd 
for C14H21O7, 301.1287).  
 
4.3.9. Compound (2f) 
Solid mixture; 1H NMR (CDCl3, 400 MHz) see Table 3 and δ 1.17 (3H, s, H-12), 1.22 (3H, s, 
H-13), 0.68 (3H, s, H-14), 4.69 (1H, brs, H-15a), 4.42 (1H, brs, H-15b), 4.57 (1H, d, H-1'), 4.82 
(1H, dd, H-2'), 3.63 (1H, dd, H-3'), 3.68 (1H, dd, H-4'), 3.61 (1H, qd, H-5'), 1.32 (3H, d, H-6'); 
13C NMR (CDCl3, 100 MHz) see Table 3. ESI-MS (positive mode): m/z 475 [M+Na]+; MS2 of  
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[M+Na]+: m/z 271 [M+Na-C15H24]+. EIMS of the diacetate: m/z 315 [M-C15H25O]+ (15), 204 [M-
C15H22O8] +• (19), 97 (100). HREIMS: m/z 315.1447 (calcd for C15H23O7, 315.1444).   
 
4.3.10. Compound (3) 
White, amorphous powder; [α]25D –9.5 (c 0.6, isopropanol); 1H NMR (CDCl3, 400 MHz) see 
Table 1; 1H NMR (CD3OD, 400 MHz) see Table 1;  13C NMR (CDCl3, 100 MHz) see Table 2. 
HR-ESI-MS (positive mode): m/z 391.2461 [M+Na]+; (calcd. for C21H36O5Na, 391.2455).  
 
4.3.11. Compound (3d) 
White, amorphous powder; [α]25D –6.8 (c 0.15, CHCl3); 1H NMR (CDCl3, 400 MHz) see 
Table 1 and δ 5.63 (1H, m, J = 1.3 Hz, H-2"), 2.18 (2H, qd, J = 7.5, 1.1 Hz, H-4"), 1.08 (3H, t, J 
= 7.5 Hz, H-5"), 2.16 (3H, d, J = 1.3 Hz, H-6"); 1H NMR (CD3OD, 400 MHz) see Table 1 and δ 
5.66 (1H, m, H-2"), 2.20 (2H, qd, H-4"), 1.09 (3H, t, H-5"), 2.16 (3H, d, H-6"); 13C NMR 
(CDCl3, 100 MHz) see Table 2 and δ 166.7 (C, C-1"), 113.6 (CH, C-2"), 163.5 (C, C-3"), 33.9 
(CH2, C-4"), 11.7 (CH3, C-5"), 18.8 (CH3, C-6"); ESI-MS (positive mode): m/z 487 [M+Na]+; 
MS2 of  [M+Na]+: m/z 283 [M+Na-C15H24]+; MS3 of [M+Na]+ → [M+Na-C15H24]+: m/z 265 
[M+Na-C15H24-H2O]+. ESI-MS (negative mode): m/z 463 [M-H]‾; MS2 of  [M-H]‾: m/z 367 [M-
H-C6H8O]‾; MS3 of [M-H]‾ → [M-H-C6H8O]‾: m/z 145 [M-H-C6H8O-C15H26O]‾.  
 
4.3.12. Compound (3a) 
White, amorphous powder; 1H NMR (CDCl3, 400 MHz) δ 1.68 (1H, m, H-5), 0.03 (1H, t, H-
6), 0.55 (1H, td, H-7), 0.89 (3H, s, H-12), 0.98 (3H, s, H-13), 1.17 (3H, s, H-14), 0.87 (3H, d, H-
15), 4.65 (1H, d, H-1'), 4.98 (1H, dd, H-2'), 3.64 (1H, dd, H-3'), 3.68 (1H, dd, H-4'), 3.61 (1H, qd, 
H-5'), 1.30 (3H, d, H-6'), 6.13 (1H, qq, J = 7.3, 1.4 Hz, H-3"), 2.01 (3H, dq, J = 7.3, 1.5 Hz, H-
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4"), 1.89 (3H, m, H-5"); 1H NMR (CD3OD, 400 MHz) δ 1.70 (1H, m, H-5), 0.09 (1H, t, H-6), 
0.57 (1H, ddd, H-7), 0.92 (3H, s, H-12), 0.99 (3H, s, H-13), 1.18 (3H, s, H-14), 0.88 (3H, d, H-
15), 4.68 (1H, d, H-1'), 5.02 (1H, dd, H-2'), ~3.65 (3H, m, H-3' and H-4' and H-5'), 1.24 (3H, d, 
H-6'), 6.18 (1H, qq, H-3"), 2.02 (3H, dq, H-4"), 1.90 (3H, m, H-5") 13C NMR (CDCl3, 100 MHz) 
δ 54.8 (CH, C-1), 82.0 (C, C-10), 94.7 (CH, C-1'), 73.2 (CH, C-2'), 167.8 (C, C-1"), 126.9 (C, C-
2"), 139.6 (CH, C-3"), 16.0 (CH3, C-4"), 20.5 (CH3, C-5"); ESI-MS (positive mode): m/z 473 
[M+Na]+; MS2 of  [M+Na]+: m/z 269 [M+Na-C15H24]+. EIMS of the diacetate: m/z 534 [M]+• 
(0.4), 313 [M-C15H25O]+ (33), 204 [M-C15H22O8] +• (85), 83 (100). HREIMS: m/z 534.3177 
(calcd. for C30H46O8, 534.3193), 313.1285 (calcd. for C15H21O7, 313.1287), 204.1875 (calcd. for 
C15H24, 204.1878).  
 
4.3.13. Compound (3b) 
Solid mixture; 1H NMR (CDCl3, 400 MHz) δ 0.01 (1H, t, H-6), 0.54 (1H, td, H-7), 0.85 (3H, 
s, H-12), 0.97 (3H, s, H-13), 1.18 (3H, s, H-14), 0.83 (3H, d, H-15), 4.64 (1H, d, H-1'), 4.98 (1H, 
dd, H-2'), 1.31 (3H, d, H-6'), 6.87 (1H, qq, J = 7.0, 1.4 Hz, H-3"), 1.79 (3H, dq, J = 7.0, 1.2 Hz, 
H-4"), 1.83 (3H, m, H-5"); 13C NMR (CDCl3, 100 MHz) δ 81.5 (C, C-10), 94.7 (CH, C-1'), 167.4 
(C, C-1"), 128.0 (C, C-2"), 137.6 (CH, C-3"), 14.4 (CH3, C-4"), 12.1 (CH3, C-5"). EIMS of the 
diacetate: m/z 534 [M]+• (0.1), 313 [M-C15H25O]+ (0.9), 204 [M-C15H22O8] +• (2.5), 80 (100). 
HREIMS: m/z 313.1283 (calcd. for C15H21O7, 313.1287), 204.1875 (calcd. for C15H24, 204.1878). 
 
4.3.14. Compound (3c) 
Solid mixture; 1H NMR (CDCl3, 400 MHz) δ 0.03 (1H, t, H-6), 0.55 (1H, td, H-7), 0.84 (3H, 
s, H-12), 0.97 (3H, s, H-13), 1.18 (3H, s, H-14), 0.87 (3H, d, H-15), 4.61 (1H, d, H-1'), 4.88 (1H, 
dd, H-2'), 1.31 (3H, d, H-6'), 5.64 (1H, m, J = 1.3 Hz, H-2"), 1.90 (3H, d, J = 1.3 Hz, H-4"), 2.17 
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(3H, d, J = 1.3 Hz, H-5"); 13C NMR (CDCl3, 100 MHz) δ 81.3 (C, C-10), 95.1 (CH, C-1'), 166.5 
(C, C-1"), 115.1 (CH, C-2"), 158.6 (C, C-3"), 27.4 (CH3, C-4"), 20.2 (CH3, C-5"). EIMS and 
HREIMS of the diacetate are identical to those for compound 3b. 
 
4.3.15. Compound (3e) 
White, amorphous powder; 1H NMR (CDCl3, 400 MHz) δ 1.73 (1H, m, H-5), 0.06 (1H, t, H-
6), 0.57 (1H, td, H-7), 0.94 (3H, s, H-12), 1.00 (3H, s, H-13), 1.17 (3H, s, H-14), 0.91 (3H, d, H-
15), 4.60 (1H, d, H-1'), 4.83 (1H, dd, H-2'), 3.58 (1H, dd, H-3'), 3.66 (1H, dd, H-4'), 3.57 (1H, qd, 
H-5'), 1.30 (3H, d, H-6'), 2.55 (1H, m, J = 7.0 Hz, H-2"), 1.17 (3H, d, J = 7.0 Hz, H-3"), 1.21 
(3H, d, J = 7.0 Hz, H-4"); 1H NMR (CD3OD, 400 MHz) δ  ~1.76 (1H, m, H-5), 0.12 (1H, t, H-6), 
0.59 (1H, ddd, H-7), 0.96 (3H, s, H-12), 1.01 (3H, s, H-13), 1.18 (3H, s, H-14), 0.92 (3H, d, H-
15), 4.64 (1H, d, H-1'), 4.94 (1H, dd, H-2'), ~3.62 (3H, m, H-3' and H-4' and H-5'), 1.23 (3H, d, 
H-6'), 2.54 (1H, m, H-2"), 1.16 (3H, d, H-3"), 1.20 (3H, d, H-4"); 13C NMR (CDCl3, 100 MHz) δ 
55.1 (CH, C-1), 82.1 (C, C-10), 94.6 (CH, C-1'), 73.6 (CH, C-2'), 177.6 (C, C-1"), 34.1 (CH, C-
2"), 18.5 (CH3, C-3"), 19.6 (CH3, C-4"); ESI-MS (positive mode): m/z 461 [M+Na]+; MS2 of  
[M+Na]+: m/z 257 [M+Na-C15H24]+.  
 
4.4. Basic hydrolysis  
A portion of the crude fraction H from FC (~50 mg) was dissolved in MeOH (2.5 mL), mixed 
to a soln. of KOH (1 M, 2.5 mL) in a round bottomed flask and stirred at 40 °C for 20 h. After 
cooling at room temperature, the solution was neutralized with formic acid (~ 0.25 mL). RP18 
gel for FC (1 spoon) was added to the clear solution and the solvent was evaporated. The 
desiccated slurry was applied to a short FC column packed with RP18, washed with water and 
eluted with methanol. The solvent was finally evaporated to give the sesquiterpene glycosides 
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mixture (~40 mg) that was purified by reversed phase HPLC. The eluents were MeOH−H2O 
(75:25) and the detection wavelength was set at 210 nm. Three main fractions were collected that 
contained the compounds 1 (tR=13.1 min, mg 6.7), 2 (tR=15.5 min, mg 14.5) and 3 (tR=21.1 min, 
mg 9.2). 
 
4.5. Acid hydrolysis  
The acidic hydrolysis of sesquiterpene glycosides was carried out by a microwave-assisted 
method (Xiping and Yangde, 2008). A portion of the saponified mixture was dissolved in a 
solution prepared with 1.4 mL of i-PrOH−H2O (50:50) and 0.28 mL of concentrated HCl (36%) 
that was transferred in a microwave vessel and placed on the turntable of the microwave oven. 
Hydrolysis progressed for 2 min using 300 W of microwave radiation power at the temperature 
80 ºC. The reaction mixture was then neutralized with aqueous Na2CO3 (0.35 g in 5 mL), 
transferred to a separating funnel and repeatedly extracted with n-hexane. The polar phase was 
concentrated and purified by prep. TLC (CHCl3−MeOH−H2O, 60:34:6) to give pure fucose 
(Rf=0.32, 15 mg). The sugar was identified by its proton NMR spectra and gave a specific optical 
rotation ([α]D = +22.7 (c = 0.79, water)) which is consistent with the D-enantiomer.  
 
4.6. Acetylation  
The compounds 1a, 2a, 2b+2c+2e, 2d+2f, 3a, 3b+3c and 3d were subjected to esterification 
of the hydroxyls HO-3' and HO-4'. Dry pyridine (20µL) and acetic anhydride (20µL) were added 
under nitrogen to each sample (~0.4 mg) in a small screw-capped vial. The solution was allowed 
to stand at room temperature for 2 days and then evaporated. The residue was dissolved in 
methanol and analyzed by EI-MS without any preliminary purification. Only the diacetate 
products could be detected. The abundant compounds 1a, 2a and 3d were also investigated by 
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NMR spectroscopy thus revealing that the yield of acetylation was nearly quantitative without 
any detectable by-product. 
 
4.6.1. Diacetate of compound (1a):  
1H NMR (CDCl3, 400 MHz) δ 5.78 (1H, dd, J = 17.8, 10.6 Hz, H-1), 4.87 (2H, m, H-2), 4.78 
(1H, m, H-3a), 4.55 (1H, brs, H-3b), 1.13 (3H, s, H-12), 1.21 (3H, s, H-13), 0.95 (3H, s, H-14), 
1.68 (3H, brs, H-15), 4.66 (1H, d, J = 7.8 Hz, H-1'), 5.28 (1H, dd, J = 7.8, 10.3 Hz, H-2'), 5.11 
(1H, dd, J = 10.3, 3.4 Hz, H-3'), 5.22 (1H, dd, J = 3.4, 1.1 Hz, H-4'), 3.79 (1H, qd, J = 1.1, 6.4 
Hz, H-5'), 1.20 (3H, d, J = 6.4 Hz, H-6'), 6.07 (1H, qq, J = 7.3, 1.5 Hz, H-3"), 1.95 (3H, dq, J = 
7.3, 1.5 Hz, H-4"), 1.83 (3H, qd, J = 1.5 Hz, H-5"), 2.16 (3H, s, AcO-4'), 1.94 (3H, s, AcO-3'). 
EIMS: m/z 534 [M]+• (0.1), 313 [M-C15H25O]+ (11), 204 [M-C15H22O8] +• (18), 83 (100). 
HREIMS: m/z 534.3187 (calcd. for C30H46O8, 534.3192), 476.2782 (calcd. for C27H40O7, 
476.2774), 313.1284 (calcd. for C15H21O7, 313.1287), 204.1873 (calcd. for C15H24, 204.1878). 
 
4.6.2. Diacetate of compound (2a):  
1H NMR (CDCl3, 400 MHz) δ ~2.28 (1H, brd, H-3β), 1.12 (3H, s, H-12), 1.20 (3H, s, H-13), 
0.66 (3H, s, H-14), 4.68 (1H, brs, H-15a), 4.43 (1H, brs, H-15b), 4.67 (1H, d, J = 7.8 Hz, H-1'), 
5.29 (1H, dd, J = 7.8, 10.4 Hz, H-2'), 5.11 (1H, dd, J = 10.4, 3.5 Hz, H-3'), 5.22 (1H, dd, J = 3.5, 
1.1 Hz, H-4'), 3.78 (1H, qd, J = 1.1, 6.4 Hz, H-5'), 1.19 (3H, d, J = 6.4 Hz, H-6'), 6.07 (1H, qq, J 
= 7.3, 1.5 Hz, H-3"), 1.96 (3H, dq, J = 7.3, 1.5 Hz, H-4"), 1.84 (3H, qd, J = 1.5 Hz, H-5"), 2.17 
(3H, s, AcO-4'), 1.95 (3H, s, AcO-3'). EIMS: m/z 534 [M]+• (0.1), 313 [M-C15H25O]+ (1.2), 204 
[M-C15H22O8] +• (1.5), 80 (100). HREIMS: m/z 534.3184 (calcd. for C30H46O8, 534.3193), 
313.1285 (calcd. for C15H21O7, 313.1287), 204.1880 (calcd. for C15H24, 204.1878). 
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4.6.3. Diacetate of compound (3d):  
1H NMR (CDCl3, 400 MHz) δ 0.02 (1H, t, J = 9.5 Hz, H-6), 0.55 (1H, td, J = 9.5, 9.5, 7.6 Hz, 
H-7), 0.83 (3H, s, H-12), 0.96 (3H, s, H-13), 1.17 (3H, s, H-14), 0.83 (3H, d, J = 6.7 Hz, H-15), 
4.69 (1H, d, J = 8.0 Hz, H-1'), 5.24 (1H, dd, J = 8.0, 10.4 Hz, H-2'), 5.02 (1H, dd, J = 10.4, 3.5 
Hz, H-3'), 5.20 (1H, dd, J = 3.5, 1.1 Hz, H-4'), 3.74 (1H, qd, J = 1.1, 6.4 Hz, H-5'), 1.18 (3H, d, J 
= 6.4 Hz, H-6'), 5.54 (1H, tq, J = 1.3 Hz, H-2"), 2.16 (2H, qd, H-4"), 1.06 (3H, t, J = 7.5 Hz, H-
5"), 2.14 (3H, d, J = 1.3 Hz, H-6"), 2.16 (3H, s, AcO-4'), 1.94 (3H, s, AcO-3'). EIMS of the 
diacetate: m/z 548 [M]+• (0.1), 327 [M-C15H25O]+ (15), 204 [M-C15H22O8] +• (94), 97 (100). 
HREIMS: m/z 327.1438 (calcd. for C16H23O7, 327.1444), 204.1876 (calcd. for C15H24, 204.1878).  
 
4.7. Cytotoxicity assays  
Cytotoxicity of fractions and individual compounds was performed in human epithelial gastric 
cells AGS by MTT assay and LDH release. For MTT assay, cells were treated with fractions (10 
µg/mL) or individual molecules (5-20 µM) for 24 h; the final concentration of the vehicle 
(DMSO) was 0.2%. Then, growth media were removed and 200 µL of phosphate-buffered saline 
(PBS) containing MTT, at a final concentration of 0.1 mg/mL, was added to each well. After 1 h 
incubation at 37 °C, MTT dye was removed and 200 µL/well of extracting solution (i-
PrOH−DMSO, 9:1) was added. Absorbance was measured on a microplate reader at 550 nm. 
Cells treated with Triton-X100 1% for 24 h were used as positive control (around 100% 
inhibition of cell viability). Treatment effects on cellular viability were expressed by setting the 
percentage of cells treated only with this vehicle at 100%. LDH release was measured with the 
LDH Cytotoxicity Detection Kit (Takara Bio Inc.) following the manufacturer’s instructions. 
Briefly, 24 h after treatment with compounds (final concentration of DMSO was 0.2%), samples 
were centrifuged, and 100 µL of medium of each well was added to 100 µL of a reaction mixture 
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containing a catalyst and a dye solution. Samples were incubated for 15 minutes at room 
temperature, and LDH activity was quantified measuring the absorbance at 490 nm on a 
microplate reader. A medium of AGS cells treated with Triton-X100 1% for 24 h was used as a 
positive control (around 90% inhibition of cell viability). Cytotoxicity of fractions (5-20 µg/mL) 
and individual compounds (5-20 µM) was calculated as a percentage, setting the control viability 
treated only with the vehicle at 100%. Experiments, including those used to calculate IC50, were 
performed three times in triplicate and the average values ± S.D. were reported.  
 
4.8. In vitro digestion of CH2Cl2 extract   
Gastric digestion was simulated using a protocol previously described, with minor 
modifications (Oomen et al., 2003; Versantvoort et al., 2005). Briefly, CH2Cl2 extract (60 mg) 
was incubated for 5 min at 37 °C with 0.6 mL of saliva juice (12 mM KCl, 2 mM KSCN, 7.4mM 
NaH2PO4, 4 mM Na2SO4, 5 mM NaCl, 1.8 mM NaOH, 3.3 mM urea, 89 µM uric acid, 145 mg/L 
amylase and 50 mg/L mucin). Then 1.2 mL of gastric juice (47 mM NaCl, 2.2 mM NaH2PO4, 11 
mM KCl, 2.7 mM CaCl2, 5.7 mM NH4Cl, 8.3 mL/L HCl, 3.6 mM glucose, 0.1 mM glucuronic 
acid, 1.4 mM urea, 1.5 mM glucosaminehydrochloride, 1 g/L BSA, 1 g/L pepsin and 3 g/L mucin) 
was added to the suspension and the sample was incubated for 2 h at 37°C. At the end of the 
incubation, the digested sample was frozen and lyophilized. The crude extract and lyophilized 
mixture were dissolved in methanol and then analyzed by HPLC over the Luna CN column: the 
chromatographic profiles were quite similar particularly in the region where the sesquiterpene 
glycosides were eluted. This suggests that sesquiterpene glycosides are unaffected by the in vitro 
digestive treatment. 
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